107 related articles for article (PubMed ID: 22787088)
1. Selective activation of oxygen-deprived tumor-infiltrating lymphocytes through local intratumoral delivery of CD137 monoclonal antibodies.
Melief CJ
Cancer Discov; 2012 Jul; 2(7):586-7. PubMed ID: 22787088
[TBL] [Abstract][Full Text] [Related]
2. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
Weigelin B; Bolaños E; Rodriguez-Ruiz ME; Martinez-Forero I; Friedl P; Melero I
Cancer Immunol Immunother; 2016 May; 65(5):493-7. PubMed ID: 26970765
[TBL] [Abstract][Full Text] [Related]
4. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
5. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
6. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Eskiocak U; Guzman W; Wolf B; Cummings C; Milling L; Wu HJ; Ophir M; Lambden C; Bakhru P; Gilmore DC; Ottinger S; Liu L; McConaughy WK; He SQ; Wang C; Leung CL; Lajoie J; Carson WF; Zizlsperger N; Schmidt MM; Anderson AC; Bobrowicz P; Schuetz TJ; Tighe R
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161196
[TBL] [Abstract][Full Text] [Related]
7. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.
Kwong B; Gai SA; Elkhader J; Wittrup KD; Irvine DJ
Cancer Res; 2013 Mar; 73(5):1547-58. PubMed ID: 23436794
[TBL] [Abstract][Full Text] [Related]
8. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
[TBL] [Abstract][Full Text] [Related]
9. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.
Dubrot J; Milheiro F; Alfaro C; Palazón A; Martinez-Forero I; Perez-Gracia JL; Morales-Kastresana A; Romero-Trevejo JL; Ochoa MC; Hervás-Stubbs S; Prieto J; Jure-Kunkel M; Chen L; Melero I
Cancer Immunol Immunother; 2010 Aug; 59(8):1223-33. PubMed ID: 20336294
[TBL] [Abstract][Full Text] [Related]
10. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB-Enhanced Expansion of CD8
Harao M; Forget MA; Roszik J; Gao H; Babiera GV; Krishnamurthy S; Chacon JA; Li S; Mittendorf EA; DeSnyder SM; Rockwood KF; Bernatchez C; Ueno NT; Radvanyi LG; Vence L; Haymaker C; Reuben JM
Cancer Immunol Res; 2017 Jun; 5(6):439-445. PubMed ID: 28473315
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer.
Palazón A; Aragonés J; Morales-Kastresana A; de Landázuri MO; Melero I
Clin Cancer Res; 2012 Mar; 18(5):1207-13. PubMed ID: 22205687
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
[TBL] [Abstract][Full Text] [Related]
14. Functional antibodies produced by oncolytic clostridia.
Groot AJ; Mengesha A; van der Wall E; van Diest PJ; Theys J; Vooijs M
Biochem Biophys Res Commun; 2007 Dec; 364(4):985-9. PubMed ID: 17971292
[TBL] [Abstract][Full Text] [Related]
15. Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity.
Qiao Y; Qiu Y; Ding J; Luo N; Wang H; Ling X; Sun J; Wu Z; Wang Y; Liu Y; Guo F; Sun T; Shen W; Zhang M; Wu D; Chen B; Xu W; Wang X
Nat Commun; 2021 Nov; 12(1):6360. PubMed ID: 34737267
[TBL] [Abstract][Full Text] [Related]
16. The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention.
Luu K; Shao Z; Schwarz H
J Leukoc Biol; 2020 May; 107(5):731-738. PubMed ID: 32052477
[TBL] [Abstract][Full Text] [Related]
17. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Barsoum IB; Smallwood CA; Siemens DR; Graham CH
Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
[TBL] [Abstract][Full Text] [Related]
18. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
19. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer.
Sabel MS; Su G; Griffith KA; Chang AE
Breast Cancer Res Treat; 2010 Jul; 122(2):325-36. PubMed ID: 19802695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]